Papers/PMID:33761699
Increased bleeding events with the addition of apixaban to the dual anti-platelet regimen for the treatment of patients with acute coronary syndrome: A meta-analysis.
Medicine2021The record
2 findings · 1 compound · 2 endpoints · 2 null
What it reported
How to read these marksEvery finding here is a null result.
What did not
2 findings
apixaban — no detected effect on all-cause mortality
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“When the cardiovascular outcomes were assessed, no significant change was observed in all-cause mortality (OR: 1.12, 95% CI: 0.89–1.40; P =.33), MACEs (OR: 0.96, 95% CI: 0.82–1.14; P =.67), stroke (OR: 0.73, 95% CI: 0.44–1.20; P =.22), stent thrombosis (OR: 0.72, 95% CI: 0.47–1.12; P =.15), and MI (OR: 0.92, 95% CI: 0.75–1.13; P =.44) when apixaban was added to DAPT as shown in Figure 4.”
Quoted verbatim from Increased bleeding events with the addition of apixaban to the dual anti-platelet regimen for the treatment of patients with acute coronary syndrome: A meta-analysis.. - Study
- meta-analysis
- Population
- Patients with acute coronary syndrome, pooled across 4 RCTs; apixaban plus aspirin and clopidogrel (DAPT) versus DAPT alone
Effect 1.12 odds ratio, 95% CI 0.89 to 1.4
Increased bleeding events with the addition of apixaban to the dual anti-platelet regimen for the treatment of patients with acute coronary syndrome: A meta-analysis.2021PMID:33761699Permalink
apixaban — no detected effect on incidence of stroke
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“When the cardiovascular outcomes were assessed, no significant change was observed in all-cause mortality (OR: 1.12, 95% CI: 0.89–1.40; P =.33), MACEs (OR: 0.96, 95% CI: 0.82–1.14; P =.67), stroke (OR: 0.73, 95% CI: 0.44–1.20; P =.22), stent thrombosis (OR: 0.72, 95% CI: 0.47–1.12; P =.15), and MI (OR: 0.92, 95% CI: 0.75–1.13; P =.44) when apixaban was added to DAPT as shown in Figure 4.”
Quoted verbatim from Increased bleeding events with the addition of apixaban to the dual anti-platelet regimen for the treatment of patients with acute coronary syndrome: A meta-analysis.. - Study
- meta-analysis
- Population
- Patients with acute coronary syndrome, pooled across 4 RCTs; apixaban plus aspirin and clopidogrel (DAPT) versus DAPT alone
Effect 0.73 odds ratio, 95% CI 0.44 to 1.2
Increased bleeding events with the addition of apixaban to the dual anti-platelet regimen for the treatment of patients with acute coronary syndrome: A meta-analysis.2021PMID:33761699Permalink